MedTrace Logo

Clinical Study of CVL006 Combination With 9MW2821

NCT07615660 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2026-05-29

No results posted yet for this study

Summary

This study is a multi-center, open-label, dose-escalation and dose-optimized phase I/II clinical trial. Objective: To determine the safety, tolerability, PK characteristics and preliminary efficacy data of CVL006 combined with 9MW821 patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

CVL006 in combination with 9MW2821

CVL006 in combination with 9MW2821

DRUG

CVL006 in combination with 9MW2821

CVL006 in combination with 9MW2821

Sponsors & Collaborators

  • Convalife (Shanghai) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-15
Primary Completion
2029-04-30
Completion
2029-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07615660 on ClinicalTrials.gov